Modality
mRNA
MOA
BCL-2i
Target
BTK
Pathway
Tau
Alzheimer'sRCCEpilepsy
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Aug 2026
Phase 1Current
NCT05947358
2,852 pts·Alzheimer's
2019-12→2026-08·Completed
NCT05881920
1,513 pts·Epilepsy
2021-06→TBD·Active
4,365 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-195mo awayInterim· Alzheimer's
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2026-08-19 · 5mo away
Alzheimer's
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05947358 | Phase 1 | Alzheimer's | Completed | 2852 | UPDRS |
| NCT05881920 | Phase 1 | Epilepsy | Active | 1513 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| 369-8021 | Hansoh Pharma | Approved | BTK |